
#311Medicine & HealthFront Page12 February 2026
SGLT2 inhibitors vs DPP4 inhibitors: Weighing the Evolutionary Costs of Sugar Control
A new meta-analysis of 42 randomised controlled trials contrasts the safety profiles of two dominant diabetes therapies. While generally safe, the data reveals a sharp trade-off: effective glucose excretion comes at the price of significantly higher genitourinary infection risks.
By Li, Chen, Gao, Zhang, Deng, Li, Zhang, Li